At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 50 target
Drug / intervention
Skin drug prepared with exome originated from stem celldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical Trial
Second Affiliated Hospital of Guangzhou Medical University·interventional·Posted Jun 28, 2024·Updated Jun 28, 2024
In Brief
A Phase 2 clinical trial evaluating Skin drug prepared with exome originated from stem cell for Diabetic Foot and Stem Cell. Not yet recruiting, targeting 50 participants across 1 site.
Detailed Summary
This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Foot, Stem Cell
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet Recruiting
2025202620272028202920302031203220332034
First PostedJun 2024
Enrollment StartAug 2024
TodayJul 2026
Primary CompletionDec 2028
Study CompletionDec 2033
First PostedJun 28, 2024
Enrollment StartAug 1, 2024
Primary CompletionDec 30, 2028
Study CompletionDec 30, 2033
TodayJul 1, 2026
Enrollment to primary: 4.4 yearsPosted 2.0 years agoPrimary completion in 2.5 years
Interventions
Skin drug prepared with exome originated from stem celldrug
Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.